Brain edema in neurooncology:: Radiological assessment and management

被引:60
作者
Wick, W
Küker, W
机构
[1] Univ Tubingen, Sch Med, Dept Neuroradiol, Tubingen, Germany
[2] Univ Tubingen, Hartie Inst Clin Brain Res, Dept Gen Neurol, Ctr Neurol, D-72076 Tubingen, Germany
来源
ONKOLOGIE | 2004年 / 27卷 / 03期
关键词
brain tumor; COX-2; DW-MRI; steroids; Vasogenic Odem; VEGF;
D O I
10.1159/000077976
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Vasogenic brain edema is a common diagnostic and management problem in brain tumor patients. Molecular mechanisms play a role in the pathophysiology, including abnormalities of tumor endothelium, vascular endothelial growth factor and leukotriene synthase. Edema diagnosis is facilitated by the development of neuroradiological imaging techniques, with diffusion-weighted imaging (DW-MRI) differentiating tumor grades or abscesses and tumors, and diffusion tensor imaging representing an advanced technique to potentially differentiate malignant glioma from metastasis or facilitate preoperative planning. Edema is a prognostic factor for meningioma and metastases but not for glioma. Therapy includes, amongst others, tumor-directed measures such as debulking surgery, radio- and chemotherapy. However, local therapeutic approaches might also induce or exacerbate edema formation. Peritumoral edema can usually be managed with corticosteroids. However, patients on corticosteroids are at greater risk of metabolic changes, Pneumocystis carinii pneumonia, and thromboembolism. More recently, inhibitors of cyclooxygenase-2 as well as boswellic acids have been explored as antiedema agents in patients with brain tumors.
引用
收藏
页码:261 / 266
页数:6
相关论文
共 40 条
[21]  
Marras LC, 2000, CANCER, V89, P640, DOI 10.1002/1097-0142(20000801)89:3<640::AID-CNCR20>3.0.CO
[22]  
2-E
[23]  
Mckeran R.O., 1980, Brain Tumours: scientific basis, clinical investigation and current therapy, ed, P194
[24]   The eicosanoid cascade: possible role in gliomas and meningiomas [J].
Nathoo, N ;
Barnett, GH ;
Golubic, M .
JOURNAL OF CLINICAL PATHOLOGY, 2004, 57 (01) :6-13
[25]   Dose escalation of carmustine in surgically implanted polymers in patients with recurrent malignant glioma: A new approaches to Brain Tumor Therapy CNS Consortium trial [J].
Olivi, A ;
Grossman, SA ;
Tatter, S ;
Barker, F ;
Judy, K ;
Olsen, J ;
Bruce, J ;
Hilt, D ;
Fisher, J ;
Piantadosi, S .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (09) :1845-1849
[26]   Expression and distribution of vascular endothelial growth factor protein in human brain tumors [J].
Pietsch, T ;
Valter, MM ;
Wolf, HK ;
vonDeimling, A ;
Huang, HJS ;
Cavenee, WK ;
Wiestler, OD .
ACTA NEUROPATHOLOGICA, 1997, 93 (02) :109-117
[27]   VASCULAR ENDOTHELIAL GROWTH-FACTOR IS A POTENTIAL TUMOR ANGIOGENESIS FACTOR IN HUMAN GLIOMAS INVIVO [J].
PLATE, KH ;
BREIER, G ;
WEICH, HA ;
RISAU, W .
NATURE, 1992, 359 (6398) :845-848
[28]  
POSNER JB, 1995, NEUROLOGIC COMPLICAT, P44
[29]   Meningiomas: Role of vascular endothelial growth factor vascular permeability factor in angiogenesis and peritumoral edema [J].
Provias, J ;
Claffey, K ;
delAguila, L ;
Lau, N ;
Feldkamp, M ;
Guha, A .
NEUROSURGERY, 1997, 40 (05) :1016-1026
[30]   Glioblastoma cells release factors that disrupt blood-brain barrier features [J].
Schneider, SW ;
Ludwig, T ;
Tatenhorst, L ;
Braune, S ;
Oberleithner, H ;
Senner, V ;
Paulus, W .
ACTA NEUROPATHOLOGICA, 2004, 107 (03) :272-276